(Total Views: 634)
Posted On: 06/26/2020 9:10:13 AM
Post# of 154138
Thoughts on this post ??
So now that Dr. Patterson has patented tests that can find markers for this, the next step is to stratify high risk patient populations and then test those populations for these markers. That has immense ramifications going foward re these patients susceptibility for Covid and many other disease processes.
Of course this is a new frontier of medicine and not everyone will buy into this out of the gate, and this has the potential to disintermediate a lot of stuff in health care. This is why I am working with Dr. P and a actuary friend of mine to take this idea to one of the big managed care organizations as we believe this can be strong predictor of future health issues. Finally that begs a huge question as to whether or not Leron could be repurposed and priced accordingly to use it as a preventative measure in some of this high risk population. Just with the Medicare Advantage population, which totals roughly 22 million Medicare beneficiaries, I am guessing this could be a $2 to $4 billion dollar use, notwithstanding the math of this on the remainder of the Medicare population as well as the under 65 population. There are several second and third order ideas around the RANTES' theory.
So now that Dr. Patterson has patented tests that can find markers for this, the next step is to stratify high risk patient populations and then test those populations for these markers. That has immense ramifications going foward re these patients susceptibility for Covid and many other disease processes.
Of course this is a new frontier of medicine and not everyone will buy into this out of the gate, and this has the potential to disintermediate a lot of stuff in health care. This is why I am working with Dr. P and a actuary friend of mine to take this idea to one of the big managed care organizations as we believe this can be strong predictor of future health issues. Finally that begs a huge question as to whether or not Leron could be repurposed and priced accordingly to use it as a preventative measure in some of this high risk population. Just with the Medicare Advantage population, which totals roughly 22 million Medicare beneficiaries, I am guessing this could be a $2 to $4 billion dollar use, notwithstanding the math of this on the remainder of the Medicare population as well as the under 65 population. There are several second and third order ideas around the RANTES' theory.
(1)
(0)
